Neisseria meningitidis is a commensal of the human nasopharynx but is also a major cause of septicemia and meningitis. The meningococcal factor H binding protein (fHbp) binds human factor H (fH), enabling downregulation of complement activation on the bacterial surface. fHbp is a component of two serogroup B meningococcal vaccines currently in clinical development. Here we characterize 12 fHbp sub-variants for their level of surface exposure and ability to bind fH, mediate serum resistance and induce bactericidal antibodies. Flow cytometry and Western analysis revealed that all strains examined expressed fHbp on their surface to different extents and bound fH in an fHbp-dependent manner. However, differences in fH binding did not always correlate with the level of fHbp expression, indicating that this is not the only factor affecting the amount of fH bound. To overcome the issue of strain variability in fHbp expression, the MC58∆fHbp strain was genetically engineered to express different sub-variants from a constitutive heterologous promoter. These recombinant strains were characterized for fH binding and the data confirmed that each sub-variant binds different levels of fH.
Introduction
Disease caused by Neisseria meningitidis, including meningococcal septicemia and meningitis, is a significant health problem worldwide, the control of which is largely dependent on the availability and widespread use of vaccines (45) . The majority of meningococcal disease is caused by 5 serogroups, and effective capsular-polysaccharide and conjugate vaccines are available to prevent disease caused by serogroups A, C, W-135, Y (reviewed in 53). However, there is still no broadly protective vaccine to combat serogroup B (MenB) disease, which is the main cause of meningococcal disease in the developed world (36, 44) . The capsule polysaccharide of MenB is highly similar to glycoproteins in human neural tissues and as such is poorly immunogenic and an unsuitable vaccine candidate (9, 33) .
However, several outer membrane proteins have been identified as potential antigens for a MenB vaccine (reviewed in 23).
Factor H binding protein (fHbp) is a meningococcal protein antigen that is currently in vaccine development (previously referred to as GNA1870 (11) and LP2086 (10) ). fHbp is a Neisseria-specific 29 kDa surface lipoprotein that binds human factor H (fH), a key inhibitor of the complement alternative pathway (14, 25) . fH is a cofactor for the factor I-mediated cleavage and inactivation of C3b and also promotes the decay of the alternative pathway C3 convertase C3bBb (reviewed in 30).
Therefore, binding of fH to fHbp on the meningococcal surface allows the pathogen to evade complement-mediated killing by the innate immune system. As such, fHbp is important for survival of bacteria in human serum and blood (25, 50, 56) . The discovery that binding of fH to N. meningitidis is specific for human fH has significant implications for the study of this organism and its species specificity (14) . fHbp induces high levels of bactericidal antibodies in mice (11) and humans (12, 18, 40, 42) (Brunelli et al., manuscript submitted), which activate bacterial killing by the classical complement pathway. Furthermore, it has been shown that binding of antibodies to fHbp can block binding of factor H, thus increasing the susceptibility of the bacterium to killing by the alternative complement pathway (25). Several other microorganisms have evolved the ability to bind fH and other complement inhibitors in order to evade complement mediated killing, and many of these proteins have also been studied for vaccine development (30) .
fHbp is expressed by almost all N. meningitidis strains studied to date (10, 26, 32) , although levels of expression vary between isolates (26, 29). Furthermore, amino acid sequence diversity exists for fHbp between strains. Several designations have been used to characterize different variants, which have been found to be antigenically poorly cross-reactive. Three variant groups, fHbp-1, fHbp-2 and fHbp-3, have been described, where fHbp-1 is the most abundant among group B meningococci (4) and sub-variant 1.1 (fHbp-1.1) is present in the multivalent Novartis MenB vaccine (4CMenB) currently in Phase III clinical trials (1, 11, 42) . Another system divides fHbp variants into subfamilies A and B, and the bivalent Pfizer (previously Wyeth) MenB vaccine that is in Phase II clinical trials contains a representative of each of these families, A05 (sub-variant 3.45) and B01 (sub-variant 1.55) (10, 20, 29, 32) . Subfamilies A and B correspond to variants 2/3 and 1, respectively. A modular architecture has also been described for fHbp that describes the overall architecture of fHbp as being comprised of combinations of 5 modular variable segments that are flanked by invariable residues, with each of the modular variable segments being derived from either variant 1 or 3 fHbp genes (2) .
The purpose of this study was to analyze a selection of the most frequently isolated fHbp subvariants, to gain a better understanding of the ability of different sub-variants to bind fH, mediate serum resistance, and induce cross protective bactericidal antibodies.
Material and Methods

Bacterial strains and culture conditions
N. meningitidis strains used in this study are described in Table 1 . N. meningitidis strains were routinely grown on chocolate agar (Biomerieaux), GC (Difco) agar supplemented with Kellogg's supplement I, or on Mueller Hinton (MH) agar (Difco) at 37°C/5% CO 2 overnight. For liquid cultures, colonies from overnight growth were used to inoculate 7 ml cultures (in MH broth supplemented with 0.25% glucose) to an OD 600 of ~0.05. The culture was incubated for approximately 1.5-2.5 h at 37ºC with shaking until early-log (OD 600 of ~ 0.25) or mid-log (OD 600 of ~ 0.5). When required, erythromycin and chloramphenicol were used at final concentrations of 5 µg/ml. Escherichia coli strains used for cloning were cultured in Luria-Bertani (LB) broth or on LB agar (Difco). When required, ampicillin, erythromycin and chloramphenicol were used at a final concentration of 100, 100 and 20 µg/ml, respectively.
Phylogenetic analysis and reconstruction of fHbp sub-variants
The fHbp gene was amplified and sequenced from different Neisseria strains as previously reported (1).
fHbp amino acid sequences were aligned using MUSCLE v3.6 (8), with default parameters. The evolutionary distances between pairs of aligned fHbp sequences were computed using the JTT matrixbased method (21) and units were scaled as number of amino acid substitutions per site, standard errors of distances were computed by bootstrap using 500 replicates. The phylogenetic reconstruction based on this distance matrix was inferred using the Neighbor-Joining method (46) . The tree branch lengths are proportional to the evolutionary distances used to infer the phylogenetic tree. All sequence alignment positions containing gaps were eliminated in pairwise sequence comparisons. Phylogenetic analyses were conducted in MEGA4 (54) . The amino acid numbering used starts from the first residue (cysteine) of the mature protein.
Cloning and expression of fHbp sub-variants in E. coli
Recombinant DNA techniques were routinely performed as described by Sambrook et al. (47) . Plasmid DNA preparations and purification of DNA fragments from PCR samples were performed using QIAGEN kits according to the manufacturer's instructions. All restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs or Roche. The recombinant proteins were obtained by cloning each gene into the pET-21b+ expression vector (Novagen) and expressing them as C-terminal histidine fusions in an E. coli heterologous system (E. coli DH5α for cloning and BL21(DE 3 ) (Invitrogen) for expression).
fHbp genes of sub-variants were amplified from the corresponding strains shown in Table 1 .
Primers 741v1f and 741v1r were used to amplify fHbp sub-variant 1 genes (except for 1.55 primers 741v1.55f and 741v1.55r were used, and for 1.4 primers 741v2,3f and 741v1r were used), primers 741v2,3f and 741v2r for sub-variant 2 genes, primers 741v2,3f and 741v3r for sub-variant 3.28, primers 741v3.13f and 741v3.13r for 3.45, and primers 741v1f and 741v2r for 1-2,3.x (see Table 2 for primer details). The expressed proteins did not contain the leader peptide. For sub-variants 1.4, 2.16, 2.19, 2.22, 2.25 and 3.28, the sequence GPDSDRLQQRRG from the gonococcal fHbp homologue was added to the N-terminal to aid expression in E. coli. PCR conditions used to amplify sub-variants are as follow: 1.1 and 1-2,3.x -5x (94°C 30s, 57°C 30s, 68°C 1 min) then 30x (94°C 30s, 68°C 30s, 68°C 1 min); 2.16 and 3.28 -5x (94°C 30s, 56°C 30s, 68°C 1 min), then 30x (94°C 30s, 71°C 30s, 68°C 1 min); for the remaining sub-variants, 94°C 2 min, 5x (94°C 30s, 52°C 30s, 68°C), 30x (94°C 30s, 65°C 30s, 68°C 1 min) then 68°C 10 min. PCR were performed on approximately 10 ng of chromosomal DNA using High Fidelity Taq DNA Polymerase (Invitrogen) as per manufacturer's instructions. PCR products were digested with NdeI as well as XhoI or HindIII, and then cloned into the NdeI/XhoI and NdeI/HindIII sites of pET-21b+. Recombinant plasmids were transformed into the E. coli expression strain. Recombinant strains were grown at 37°C to an OD 600 of 0.6-0.8 and expression of recombinant proteins was induced with 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG; Sigma).
Purification of fHbp sub-variants in E. coli
Bacterial pellets were resuspended in 10ml of B-PER (Bacterial-Protein Extraction Reagent) containing 10 µl of MgCl 2 100 mM, 50 µl of DNAse (Sigma) and 100 µl of lysozyme (Sigma), incubated for 40 min at room temperature, then centrifuged at 35000 xg for 30 min. The supernatant was collected and subjected to 2 serial purification steps using metal affinity chromatography (IMAC) and ionic exchange chromatography with a desalting step in between. All purification steps were performed using an AKTAxpress chromatographic system and monitored at OD 280 . For the IMAC purification step, filtered supernatants were automatically injected in 1ml Ni 2+ -HisTrap FF column with a flow rate of 1 ml/min, columns were washed with 20 column volumes (CV) of washing buffer (50mM NaH 2 PO 4 (Sigma), 300mM NaCl (Fluka), 30mM of Imidazole (Merck), pH 8.0). Then the Histag fusion proteins were eluted with 5 CV of elution buffer (50mM NaH 2 PO 4 , 300mM NaCl, 500mM
Imidazole, pH 8.0), and automatically loaded on 3 x 5 ml HiTrap Desalting (GE) columns connected in series and eluted with a flow rate of 5 ml/min. For ionic exchange chromatography, the eluted proteins were automatically loaded on 1ml-HiTrap Q HP, with a flow rate of 1ml/min. Subsequently, the column was washed with 10 CV of 50 mM Tris-HCl, pH8.0. The elution was set up in a linear gradient, between 50 mM Tris-HCl, pH8.0 and 50 mM Tris-HCl, 1.0 M NaCl, pH 8.0 buffer in 10 CV and 1 ml fractions were collected. Protein purity was checked by SDS-PAGE, and protein concentration was estimated using a Bradford assay.
Mice immunization
To prepare anti-fHbp polyclonal antisera, 20 µg of each recombinant protein was used to immunize 8 mice (6-week-old CD1 female mice; Charles River). The recombinant proteins were administered intraperitoneally at days 1, 21 and 35. Prior to immunization, fHbp sub-variants (100µg/ml protein)
were adsorbed onto aluminium hydroxide (Alum; 3mg/ml) in 10mM Histidine buffer pH6.5 (Sigma)
with NaCl (final osmolarity of 0.308/kg) for bactericidal assays. The solution was incubated for 15 min with stirring at room temperature and than stored overnight at 4°C. For antibodies used in flow cytometry, Freund's complete adjuvant was added to the antigen the day of immunization. Final formulations were isotonic and at physiological pH. Blood samples for analysis were taken on day 49.
The treatments were performed in accordance with internal animal ethical committee and institutional guidelines.
Flow cytometry analysis of fH binding and fHbp expression
The ability of meningococci to bind fH was determined using a FACS-Scan flow cytometer. Briefly, approximately 1x10 8 bacteria (grown in MH broth plus 0.25% glucose for approximately 2.5 h at 37ºC
with shaking until mid-log phase (OD 600 of ~ 0. 5)) were suspended in PBS+1%BSA and incubated with purified human fH (whole molecule, Calbiochem) at the quantity specified in each experiment in a final reaction volume of 100 µl, for 20 min at 37˚C. fH binding was detected using polyclonal goat anti-human fH antibodies (Calbiochem) and Donkey anti-goat IgG-FITC (Jackson Immunoresearch).
For competitive inhibition analysis of fH binding, mice polyclonal antisera specific for each fHbp subvariant (at 1:100 dilution) was incubated with bacteria for 10 min at 37˚C prior to addition of fH.
The ability of mouse polyclonal anti-fHbp sera to bind to the surface of meningococci was measured using a 1:100 dilution of mouse polyclonal anti-fHbp antiserum specific for each sub-variant.
Primary antibody binding was detected using a anti-mouse (whole molecule) FITC-conjugated antibody (Sigma) at a 1:100 dilution.
Immobilization of fH on a CM5 chip and kinetic analysis of fH binding by fHbp sub-variants
Surface Plasmon Resonance (SPR) analyses were performed using a Biacore X100 instrument (GE Healthcare). fH was coupled to a CM5-sensor chip (GE Healthcare) in 2 steps to modulate the total resonance units (RU) of immobilization, using the Biacore Amine Coupling Kit (GE Healthcare). In the first step, the carboxymethylated CM5 dextran layer was activated by a 1: 
Construction of fHbp knockout and complemented strains of N. meningitidis
The MC58∆fHbp, 961-5945∆fHbp and M1239∆fHbp mutant strains have previously been described (formerly named ∆gna1870) (26). Complementation of the MC58∆fHbp mutant with different fHbp variants was achieved by insertion of the fHbp gene, under the control of the constitutively active P tac promoter, into a noncoding chromosomal location between the 2 converging open reading frames (ORFs) NMB1428 and NMB1429, as previously described (50) . The fHbp gene was amplified from the appropriate strain in (Table 2) ) and cloned as a NdeI-NsiI fragment into the pComP RBS plasmid (50) . This plasmid was linearised with SpeI and used to transform MC58∆fHbp. Transformants were selected on chloramphenicol and checked by PCR, and complementation of the mutant strain was verified by flow cytometry. Several phase variable structures were analysed and no differences were identified in these strains for lipooligosaccharide (LOS; controlled by silver staining of LOS preparations as previously described (19)) and Opc (controlled by sequencing the repetitive DNA tracts associated with opc, using previously described primers (48)).
Ex vivo human serum models of meningococcal infection.
Bacteria were grown in MH broth plus 0.25% glucose and 0.02mM Cytidine-5'-monophospho-Nacetylneuraminic acid sodium salt (CMP-NANA) for approximately 2.5 h at 37ºC with shaking until mid-log phase (OD 600 of ~ 0. 5) then diluted in MH broth to approximately 10 5 CFU/ml. The assay was started by addition of 90µl serum to 10µl of the bacterial suspension. A sample from this mix was taken immediately and used as time 0 min. Cultures were incubated at 37°C with gentle agitation, and at various time points an aliquot of the sample was removed and the number of viable CFU were determined by plating serial dilutions onto MH agar. Experiments were performed in triplicate on several occasions. The Students' t-test was used to determine the statistical significance of survival of each complemented strain with respect to either the isogenic wild type strain or the fHbp mutant, with a p-value <0.05 considered to be significant. For preparation of human serum, whole blood was collected from healthy individuals (unimmunized against N. meningitidis and with no history of disease), coagulated at 25˚C for 30 min, centrifuged at 1,000 xg for 10 min at 4˚C and the supernatant retained.
Complement-mediated bactericidal activity
Serum bactericidal activity against N. meningitidis strains was evaluated as previously described with pooled baby rabbit serum (Pel-Freeze) (13), or human complement obtained from volunteer donors under informed consent (3). Complement donations were screened before use to ensure they lacked endogenous bactericidal activity at concentrations of both 25% and 50% in the assay and that they supported bactericidal activity. Bacteria were grown in MH broth plus 0.25% glucose for approximately 1.5 h at 37ºC with shaking until early-log phase (OD 600 of ~ 0.25) then diluted in MH broth to approximately 10 5 CFU/ml. Serum bactericidal titers were defined as the serum dilution resulting in 50% decrease in CFU/ml after 60 minutes incubation of bacteria with reaction mixture, compared to control CFU/ml at time 0. Typically, bacteria incubated with the negative control antibody in the presence of complement showed a 150 to 200% increase in CFU/ml during the 60 min incubation. The titers obtained with the sera anti-fHbp 1.1, 2.16 and 3.28 were an average of 4 different experiments. The phylogenetic tree constructed with the amino acid sequences of the 12 fHbp sub-variants used in this study (Fig. 1A) resembles the phylogenetic tree already described for the 3 variant fHbp gene. In fact, the sequence alignment highlights that the fHbp-2 sub-variants are composed of a fHbp-1 N-terminal (residues 1-97) and a fHbp-3 C-terminal (residues 98 to the stop codon). However, in this paper we refer to fHbp 1-2,3.x as a chimeric form between fHbp-1 and variants 2 and 3, since the N-terminal (from residues 1 to 191) is more similar to proteins of variant group 1 (96% identity to 1.1 in this region), and the C-terminal (from residue 192 to the stop codon) is more similar to variant groups 2 and 3 (95% identity to both 2.16 and 3.28, 56% identity to 1.1 in this region). fHbp 1.55 can also be considered as another a chimeric form, with the N-terminal (from residues 1 to 49) containing a group of amino acids typical of variant 3 molecules (96% identity to 3.28, 80% identity to 1.1 in this region), while the C-terminal (from residues 50 to the stop codon) is more similar to the variant 1 group (90% identity to 1.1). Due to the higher homology to the variant 1 group, 1.55 clusters with the variant 1 group. In general, while amino acid variations are scattered along the entire fHbp sequences, higher diversity is seen in the C-terminal part of the molecule where the majority of the bactericidal epitopes are located (13) .
Results
Characterization and phylogenetic analysis of fHbp sub-variants
N. meningitidis strains carrying different fHbp sub-variants differ in their level of surface expression and fH binding
The level of expression and surface-exposure of each fHbp sub-variant in the panel of selected strains was evaluated by flow cytometry analysis using mice polyclonal fHbp homologous antisera (i.e., antisera raised against each sub-variant). As shown in Figure 2A , all strains express fHbp on their surface regardless of the sub-variant, but the level of expression varies between strains and can be considered as high ( Binding of human fH to the surface of each of the meningococcal strains was assessed by flow cytometry using anti-fH antibodies. All 12 strains studied bind fH at the highest concentration of fH used (50µg/ml). By titrating the fH concentration used (5 and 0.5 µg/ml), differences in binding were detected, suggesting that each sub-variant has different affinity for fH. Using 0.5µg/ml fH, the highest level of binding was seen for strains carrying sub-variants 1. (Fig. 2B) . No fH binding was observed when the analysis was performed using the 3 fHbp knock out mutants, MC58∆fHbp, 961-5945∆fHbp and M1239∆fHbp, used as controls for each of the 3 variant groups, indicating that for these strains the majority of fH binding is due to fHbp.
Furthermore, we evaluated whether anti-fHbp antibodies were able to inhibit the binding of fH (using the highest fH concentration, 50µg/ml) to the surface of each bacterial strain. The results show that antibodies against each of the homologous fHbp variants have the ability to decrease the binding of fH to the cell surface (Fig. 2C) , demonstrating that in this panel of strains fHbp is responsible for the majority of fH binding.
MC58 strains engineered to express equivalent levels of fHbp sub-variants differ in their level of fH binding
In order to investigate fH binding by each fHbp sub-variant, independently of differences in expression level or strain genotype, an isogenic panel of strains was generated to express a subset of 5 of the fHbp variants described above. The isogenic panel consists of the MC58∆fHbp host strain into which the gene encoding different fHbp sub-variants was inserted in trans under the control of the constitutive P tac promoter, to enable similar levels of gene expression. Incubation of these strains with human fH, as described above, revealed that despite there being a similar level of fHbp expression between the strains (Fig. 3A) , there is a different level of binding between the variants (Fig. 3B) . The small differences seen in surface reactivity for the anti-fHbp sera are most likely a result of different immunogenicity of the proteins used to raise mouse antisera, and/or the difference in affinity of the antibodies used, rather than differences in expression. 2.6 for 2.25). These data suggest that while the ability of a strain to bind fH is influenced by the expression level of fHbp as previously reported, differences in the sequence of the sub-variants also affect fH binding.
Recombinant fHbp sub-variants differ in their ability to bind human fH
Surface Plasmon Resonance (SPR) analysis was used to investigate the interaction between fH and the purified recombinant fHbp sub-variants, in terms of binding affinity and association/dissociation kinetics. All fHbp sub-variants bound fH and kinetics of association (k a ) with fH were comparable for all variants tested (within a range of ~3 fold above or below the k a for sub-variant 1.1; Table 3 ).
However, larger differences were seen in the dissociation kinetics (k d ), which describes the stability of the complex. The most stable binding to fH was observed by sub-variants 2.25 and 3.45 (lowest k d , approximately 10 fold lower than 1.1), while the least stable fH binding is seen by sub-variants 1.14 and 1.10 (highest k d , approximately 10 fold higher than 1.1). The corresponding thermodynamic dissociation constants (K D ) are in agreement with these differences (Table 3 ). The sensorgrams for sub-variants 1.1, 1.10 and 2.25 are shown as representatives of the different stabilities of binding (Fig. 4) .
These results support the finding described above for fH binding by MC58 expressing different subvariants at equivalent levels, where 1.10 was the lowest binder and 2.25 the highest binder.
The differences seen in kinetics analysis suggest that fHbp sequence variability influences the stability of binding between fH-fHbp. In principle, residues specifically found in sub-variants with lower affinity for fH could be considered to be responsible for higher dissociation rates. On the contrary, residues specifically observed in sub-variants with higher affinity could increase the stability of the fHbp-fH complex. Although the sequence comparison of the different sub-variants did not lead to an unambiguous identification of single amino acids responsible for increased or decreased affinity for fH, a collection of residues has been identified that could affect the stability of the complex (Fig.1B) .
Serum survival of MC58 strains expressing fHbp sub-variants does not correlate with the level of fH binding
To determine if higher levels of fH binding lead to increased resistance to complement mediated killing in human serum, MC58 strains expressing different fHbp sub-variants were evaluated in an ex vivo human serum assay (Fig. 5) . The MC58∆fHbp strain is highly sensitive to killing by human serum due to the decreased binding of fH and thus the decreased inhibition of complement activation, as previously reported (26, 50). Resistance to serum killing was restored by complementation of this knockout with each of the 5 sub-variants examined, but to different degrees. The sub-variants 1.1 and 1.10 provided the greatest resistance, while sub-variants 2.16, 2.25 and 3.28 displayed 3-20 fold less survival, depending on the serum donor. This suggests that there is not a direct correlation between the amount of fH bound to the bacterial surface and the level of resistance to complement-mediated killing.
In fact, variant 1.10, which has the lowest level of fH binding, provided one of the highest levels of survival in serum to the recombinant MC58 strain.
fHbp sub-variants induce bactericidal antibodies that differ in their level of cross-protection within and between variant groups
The established correlate of protection for meningococcal disease is the serum bactericidal antibody (SBA) assay, which measures complement-mediated bacterial killing by serum antibodies. To evaluate the ability of each fHbp sub-variant to induce bactericidal antibodies against MenB strains carrying homologous or heterologous sub-variants, postimmunization sera from mice injected with each subvariant formulated with aluminium hydroxide were tested against 12 natural strains expressing the fHbp sub-variants used in this study. As shown in Table 4A in SBA assays using rabbit complement, all sub-variants induced functional bactericidal antibodies against most of the strains in the same variant group. Bactericidal titers were generally higher against strains carrying the homologous subvariant with the exception of sub-variant 1.55, which was negative for the homologous M1573 strain.
However, strain M1573 was highly resistant to killing by all polyclonal mouse antisera tested (this strain was sensitive to the anticapsular monoclonal antibody SEAM 12). However, when the anti-1.55 serum was analyzed in the bactericidal assay against a recombinant MenB strain that was engineered to express the homologous sub-variant, a bactericidal titer of 8192 was obtained, suggesting that the negative titers against the homologous strain reflects an intrinsic resistance of this strain to SBA. fHbp (Fig. 1) , did not elicit bactericidal antibodies against MC58 (expressing fHbp 1.1) possibly because of the sequence distance between these 2 sub-variants. In addition, it had no bactericidal activity against strains expressing variant 3 fHbp suggesting that the region of sequence identity does not include bactericidal epitopes. In contrast, the 1-2,3.x chimera provided a particularly broad range of coverage against strains carrying each of the 3 variant groups, which is likely due to the more pronounced hybrid nature of the protein and the presence of conserved epitopes from all 3 groups. The SBA assays were also performed using human complement (Table 4B) well as those involved in fH binding or those that are targeted by mAbs, were found to be in the upper exposed surface of the molecule (C domain), which most likely has the greatest exposure to the immune system (5, 49). It was proposed that an extended recognition site for fH exists across the entire surface of fHbp, with numerous electrostatic interactions, H-bonds and salt-bridges with both ß-barrels of fHbp (49) . Twenty amino acid residues of fHbp have been identified that interact with fH, and substitution of 2 glutamate residues led to a loss of fH binding (49) . Since one of these glutamate residues is not conserved in all the variants analyzed in this study, we speculate that other residues may be involved in fH binding. Indeed, there are several amino acid residues that are conserved in the subvariants with higher binding affinity. Residues specifically present in higher or lower affinity binders tend to cluster in three regions that contain residues known to be involved in interaction with fH ( that was complemented with sub-variant 1.10; this strain had one of the lowest levels of fH binding (~3 fold less than to 1.1) but had equivalent survival to the strain complemented with sub-variant 1.1. Subvariant 1.10 also had one of the lowest binding stabilities in SPR analyses. It is important to note that fH is present at high levels in serum (110-615 µg/ml; 0.71-3.9 µM (43)), which is in excess of the concentrations used in these studies and binding of fH to fHbp is most likely saturated even for strains with sub-variants with low binding or stability. However, fH is also present in other sites relevant to meningococcal colonization and disease, including the nasopharynx (37, 55) and the CSF (16) . The levels of fH in these sites are not well characterized, but concentrations at mucosal surfaces are expected to be ~10% of serum levels, and it has been reported that levels in CSF are <1% of those found in serum (16) . Hence, the different levels of fH binding by sub-variants may be more relevant in different niches during colonization or disease, rather than during disease in the blood. Also, it has been reported that for strain 2996, which has very low fHbp expression and negligible fH binding, that deletion of the fHbp gene leads to increased serum sensitivity (25). These data suggest that either small levels of fH binding are sufficient to provide serum resistance and/or that other host factors also play a role in fHbp dependent survival in human serum. Indeed, N. meningitidis ∆fHbp mutant strains (both sub-variant 1.1 and 1.10 strains) have been shown to be sensitive to killing by the antimicrobial peptide LL-37, indicating an additional role of fHbp (50) . This may be relevant for survival in serum, given that the precursor of LL-37, hCAP-18, is present in plasma at levels of approximately 1.2 µg/ml, which is more than 20% of the amount in circulating neutrophils (52) . The importance of various factors of the immune system in preventing meningococcal disease is indicated by the increased incidence of disease in people with deficiencies of fH or complement factors (i.e., factor I, C5 to C9) (15, 27, 35, 41) . Work is underway to determine if different sub-variants mediate different levels of resistance to LL-37 and/or additional host defenses. It was recently reported that Neisserial Surface Protein A (NspA) also binds fH, particularly in unencapsulated strains expressing lipopolysaccharide with truncated heptose I chains, and enhances meningococcal resistance to complement (22), indicating that additional factors may influence the level of fH binding by the panel of strains examined. Since more than one meningococcal protein can interact with fH it is a possibility that a specific fHbp sub-variant may be best suited to a particular strain if it has evolved a certain combination of protein variants to ensure optimal fitness in the host. This could be relevant to the level of serum resistance seen for the MC58 strains engineered to express different sub-variants; for example complementation of MC58
(normally expresses fHbp-1.1) with a sub-variant 2 or 3 protein may be less effective in mediating serum resistance than complementation with a more closely related sub-variant 1 protein.
In terms of the immunogenicity of fHbp and its ability to induce bactericidal antibodies in mice, the sub-variants analysed displayed different levels of cross-reactive bactericidal activity within each variant group in the panel of strains tested in SBA assays using both rabbit and human complement.
The majority of sub-variants were unable to induce antibodies that were cross-protective between the 3 variant groups, supporting previously published data (26). However, of particular interest was the finding that the natural 1-2,3.x chimera induces high SBA titers against sub-variants in each of the 3 variant groups. This broad coverage is likely due to the hybrid nature of the protein sequence and the presence of epitopes from both the variant 1, 2 and 3 groups. However, sub-variant 1.55 is also a hybrid between fHbp-1and fHbp-3, but a similar broad protection is not seen by this sub-variant in our experimental conditions. The lower titers and cross-reactivity seen in the SBA assays using human complement may be due to the interactions of human fH with the meningococcus and the down- relatively well conserved between variants that are required for ligand binding (6, 34, 57) , whereas M protein variants lack conserved amino acid motif or residues to explain binding (38) . N. meningitidis, as a strictly host adapted pathogen, is adept at varying its surface structures to avoid host defenses (31) .
As such, fHbp seems to have evolved to maintain conserved regions that are involved in fH recognition that enable activation of the alternative complement pathway to be decreased at the bacterial surface, but also contain a large degree of variability, which may enable bacteria to escape classical complement activation. . Alignment of the amino acid residues of the fHbp sub-variants, using sub-variant 1.1 as a reference. Residues identical to sub-variant 1.1 are shown as dots. Residues previously described to be involved in interaction with fH are colored in yellow on the 1.1 sequence. Amino acids typical of less stable fH binders (deleterious for affinity) are colored in red. Amino acids typical of more stable fH binders (potentially increasing the affinity) are colored in green (see Table 3 ). Except 1.1, used as reference sequence, the sub-variants are ordered in the alignment for increasing fH affinity, according to the surface plasmon resonance dissociation rate constant (sub-variants 1. Interaction parameters were determined by a simultaneous local fitting (black lines) with a model of equimolar stoichiometry using the BIAevaluation X100 software version 1.0. 
